Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, and the development of effective treatment strategies remains a significant challenge in the management of advanced HCC patients. The emergence of tyrosine kinase inhibitors (TKIs) has been a significant advancement in the treatment of HCC, as these targeted therapies have shown promise in prolonging the survival of patients with advanced disease. Although immunotherapy is currently considered as the first line of treatment for advanced HCC patients, many such patients do not meet the clinical criteria to be eligible for immunotherapy, and in many parts of the world there is still lack of accessibility to immunotherapy. As such, TKIs still serve as the first line of treatment and play a major role in the treatment repertoire for advanced HCC patients. However, the development of resistance to these agents is a major obstacle that must be overcome. In this review, we explore the underlying mechanisms of resistance to TKIs in HCC, the clinical implications of this resistance, and the potential strategies to overcome or prevent the emergence of resistance.
肝细胞癌是全球癌症相关死亡的主要原因，而制定有效的治疗策略仍是晚期肝细胞癌患者管理中的重大挑战。酪氨酸激酶抑制剂的出现是肝细胞癌治疗领域的重要进展，这类靶向治疗在延长晚期患者生存期方面展现出潜力。尽管免疫疗法目前被视为晚期肝细胞癌患者的一线治疗方案，但许多患者并不符合免疫疗法的临床适用标准，且全球许多地区仍无法普及免疫治疗。因此，酪氨酸激酶抑制剂仍作为一线治疗方案，在晚期肝细胞癌患者的治疗体系中发挥着重要作用。然而，耐药性的产生是当前必须克服的主要障碍。本综述将深入探讨肝细胞癌对酪氨酸激酶抑制剂产生耐药性的潜在机制、耐药性的临床意义，以及克服或预防耐药性产生的潜在策略。
肿瘤(癌症)患者之家